Evidence map›Paper›PMID 42129015›Full record

ReviewHealth economics review2026

Policy options for controlling rising hospital prices and their outcomes: a framework-based analysis.

Mohammad Ali Rezaei, Hamid Pourasghari, Ali Akbari Sari, Aziz Rezapour

Abstract readReview
In one paragraph

Review in Health economics review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohammad Ali RezaeiHospital Management Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran.
Hamid PourasghariHospital Management Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran. hamid.pourasghari@gmail.com.
Ali Akbari SariDepartment of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Aziz RezapourHealth Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRising hospital prices drive healthcare spending and threaten access, fueled by consolidation, weak regulation, and inefficient procurement. This scoping review applied the "Control Knobs" framework to identify and compare policy options for controlling hospital prices.

methodsFollowing PRISMA-ScR guidelines, PubMed, Web of Science, Scopus, Embase, and Google Scholar were searched for English-language studies (Jan 2013-Jun 2024). Studies without hospital-specific price outcomes were excluded. Two reviewers independently screened and extracted data on study characteristics, policy options, and outcomes, which were synthesized narratively across the five "Control Knobs" domains: financing, payment, organization, regulation, and behavior.

resultsOf 5,196 records, 50 studies met inclusion criteria, mostly from the U.S. (n = 30), with others from China, Italy, France, and eight additional countries. Policy options covered all five "Control Knobs" domains. Financing tools including competitive tenders, centralized procurement, and national negotiations, consistently reduced prices, particularly in China, Denmark, and India. Payment reforms, including fixed-rate contracts, price caps, reference pricing, and outcome-based procurement, generally lowered prices, though discounted-charge contracts and regional health technology assessment (HTA) sometimes increased them. Organizational changes had mixed effects. Mergers, Accountable Care Organization (ACO) acquisitions, and trauma center monopolies raised prices, while competition from ambulatory surgery centers (ASCs) and group purchasing organizations (GPOs) reduced them. Regulatory measures including caps, most-favored-nation (MFN) bans, and transparency tools, showed modest to substantial price reductions, whereas Certificates of Public Advantage (COPAs) had variable outcomes. Behavioral approaches, including HTA, biosimilar and generic entry, and public reporting, were generally associated with price declines.

conclusionHospital price control relies on the interplay of financing, payment, organizational, regulatory, and behavioral mechanisms, with financing and payment reforms exerting direct short-term effects and organizational and regulatory tools shaping long-term market dynamics. The most effective policy options enhanced competition and purchasing power, including competitive tendering, centralized procurement, and promotion of generics and biosimilars. National price negotiations and merger restrictions also contained prices, while transparency, HTA, and outcome-based contracting had modest or context-dependent effects. Some interventions, such as high-deductible health plans (HDHPs), consolidations, and poorly designed regulations, increased prices. Sustainable price control requires a coordinated, context-specific approach that ensures both affordability and equity.

Indexed as

Centralized procurementCompetitionConsolidation“Control Knobs” frameworkHealth policyHospitalmergerPriceTenderingTransparency

Identifiers

PMID42129015
PMCPMC13343954

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.